menu
    • menu
    [{"orgOrder":0,"company":"Galician Research Group on Digestive Tumors","sponsor":"Leo Pharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"SPAIN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Oncology","graph2":"Phase III","graph3":"Galician Research Group on Digestive Tumors","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Galician Research Group on Digestive Tumors \/ Leo Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Galician Research Group on Digestive Tumors \/ Leo Pharma"},{"orgOrder":0,"company":"Sunnybrook Health Sciences Centre","sponsor":"Leo Pharma | Sunnybrook Research Institute","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"CANADA","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Dalteparin sodium","moa":"Antithrombin-III","graph1":"Hematology","graph2":"Phase IV","graph3":"Sunnybrook Health Sciences Centre","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Sunnybrook Health Sciences Centre \/ Leo Pharma | Sunnybrook Research Institute","highestDevelopmentStatusID":"11","companyTruncated":"Sunnybrook Health Sciences Centre \/ Leo Pharma | Sunnybrook Research Institute"}]

    Find Clinical Drug Pipeline Developments & Deals for Dalteparin sodium

    Menu

    Dalteparin sodium

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Galician Research Group on Digestive Tumors

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Galician Research Group on Digestive Tumors

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Leo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            TINzaparin Prophylaxis in Patients With Metastatic Colorectal Cancer

                            Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Colorectal Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 23, 2022

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Leo Pharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            BioJapan
                            Not Confirmed

                            Sunnybrook Health Sciences Centre

                            Country arrow
                            BioJapan
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Hematology

                            Study Phase : Phase IV

                            Sponsor : Leo Pharma | Sunnybrook Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome

                            Details : Tinzaparin is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Venous Thrombosis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 12, 2021

                            Lead Product(s) : Dalteparin sodium

                            Therapeutic Area : Hematology

                            Highest Development Status : Phase IV

                            Sponsor : Leo Pharma | Sunnybrook Research Institute

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth